ArticleEthnicity & health2025
Racial disparities in the receipt of therapies for cancer, hypertension, and diabetes, and in mortality in a large population-based cohort of older men with prostate cancer.
Article in Ethnicity & health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundRacial disparities in treatment and mortality were widely studied among prostate cancer patients; however, few studies considered the prevalence of hypertension and diabetes and their treatment status.
objectivesTo determine whether there are racial discrepancies in the use of anti-cancer, antihypertensive, and antidiabetic drugs in a cohort of long-term survivors of prostate cancer diagnosed in 2007-2015; and to examine racial disparities in mortality after adjustments for their differences in those treatments.
methodsWe used the SEER (Surveillance, Epidemiology, and End Results)-Medicare linked database and included records for patients with prostate cancer at age 65 years or older diagnosed from 2007 to 2015 in 17 SEER areas (n = 244,468).
resultsAmong non-Hispanic Blacks with prostate cancer, 86.2% were affected by hypertension, with 62.1% taking antihypertensive medications. Additionally, 45.3% of individuals in this group had diabetes, and 41.1% of them received antidiabetic drugs to manage their respective health conditions. Non-Hispanic Blacks were less likely to receive antihypertensive drugs (adjusted odds ratio [aOR]: 0.94, 95% confidence interval [CI]: 0.89-0.99) and antidiabetic drugs (aOR:0.86, 95% CI:0.80-0.92) compared with non-Hispanic Whites. Hispanic and non-Hispanic Asians were significantly less likely to receive chemotherapy and hormone therapy, compared with non-Hispanic Whites. After adjusting for all factors including treatments, the risk of all-cause and cancer-specific mortality was significantly higher for non-Hispanic Blacks (hazard ratio: 1.22, 95% CI: 1.24-1.51 and 1.22, 95% CI:1.17-1.27) than that of non-Hispanic Whites.
conclusionsThere were substantial racial disparities in the receipt of cancer treatments and antihypertension and antidiabetic drugs. Non-Hispanic Black patients with prostate cancer still had a considerably higher risk of all-cause and cancer-specific mortality than non-Hispanic Whites after accounting for demographic, therapy, and tumor factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.